NCT06879704Recruiting
Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Quadrimodal Radiological Prediction (Ultrasound, Angiography/Mammography, Magnetic Rsonance Imaging, Positron Emission Tomography-computed Tomgraphy Scan) of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- First submitted
- 10 Mar 2025
- Start date
- 28 May 2025
- Primary completion date
- 28 Feb 2028
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT06879704
What you commit to
- Study type: Interventional
- Planned participants: 115
- From 28 May 2025 to the primary completion date, 28 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to immunotherapy
Other illness
- Inflammatory breast cancer (T4d)
- Allergies to iodine or gadolinium
Lab values
- Uncontrolled diabetes (blood glucose \>10 mmol/L)
Other
- Pregnant or breast-feeding women
- Metastatic patients
- Patient with an augmentation prosthesis (for angiography/mammography)
- Claustrophobic patients
- Renal contraindication to contrast products according to SFR-CIRTACI
- Ferromagnetic material
- Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.).
- Patient under guardianship, curatorship or safeguard of justice
Who the study is looking for
- Signed informed consent
- Patient with histologically proven TNBC
- Indication for neo-adjuvant chemo-immunotherapy treatment
- Age between 18 and 75
- Affiliated or beneficiary of a social protection scheme
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.